Evidence map›Paper›PMID 38702722›Full record

ReviewMolecular cancer2024

Ferroptotic therapy in cancer: benefits, side effects, and risks.

Jiandong Diao, Yuanyuan Jia, Enyong Dai, Jiao Liu, Rui Kang, Daolin Tang, Leng Han, Yingjie Zhong, Lingjun Meng

Abstract readReview
In one paragraph

Review in Molecular cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. [Mechanisms of Piezo1-mediated microglial ferroptosis in inhibiting spinal cord injury repair].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Induction of ferroptosis in prostate cancer by CCDC7Cell death and differentiation · 2026
    Article
  20. Review

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiandong Diao2nd Inpatient Area of Oncology and Hematology Department, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130031, China.
Yuanyuan Jia2nd Inpatient Area of Oncology and Hematology Department, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130031, China.
Enyong Dai2nd Inpatient Area of Oncology and Hematology Department, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130031, China.
Jiao LiuDAMP laboratory, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
Rui KangDepartment of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Daolin TangDepartment of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA. daolin.tang@utsouthwestern.edu.
Leng Han2nd Inpatient Area of Oncology and Hematology Department, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130031, China. hanleng@jlu.edu.cn.
Yingjie ZhongDepartment of Pediatrics, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130031, China. zhongyingj@jlu.edu.cn.
Lingjun Meng2nd Inpatient Area of Oncology and Hematology Department, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130031, China. menglj2011@jlu.edu.cn.

Funding

National Natural Science Foundation of China 32200594 and 82372152
6 · The paper itself

Abstract

Ferroptosis is a type of regulated cell death characterized by iron accumulation and uncontrolled lipid peroxidation, leading to plasma membrane rupture and intracellular content release. Originally investigated as a targeted therapy for cancer cells carrying oncogenic RAS mutations, ferroptosis induction now exhibits potential to complement chemotherapy, immunotherapy, and radiotherapy in various cancer types. However, it can lead to side effects, including immune cell death, bone marrow impairment, liver and kidney damage, cachexia (severe weight loss and muscle wasting), and secondary tumorigenesis. In this review, we discuss the advantages and offer an overview of the diverse range of documented side effects. Furthermore, we examine the underlying mechanisms and explore potential strategies for side effect mitigation.

Indexed as

FerroptosisNeoplasmsAnimalsAntineoplastic AgentsHumansAntineoplastic AgentsBenefitsCancerFerroptosisSide effectsTargeted therapy

Identifiers

PMID38702722
PMCPMC11067110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.